肝脏病学73卷增刊14期

Hepatology[Jour]AND73[volume]ANDSuppl[issue]

肝脏病学73卷增刊

CommentsfromtheEditors(编辑的评论)

1

TheDifferenceaDecadeMakes

十年的不同

GregoryJ.Gores,MarkA.McNiven,andLewisR.Roberts

Hepatology.JanuaryVolume73?Supplement1-3

Reviews(评论)

2

EpidemiologyofHepatocellularCarcinoma

肝细胞癌的流行病学

KatherineA.McGlynn,JessicaL.Petrick,andHashemB.El-Serag

Hepatology.JanuaryVolume73?Supplement4-13

3

GeneticsofHepatocellularCarcinoma:ApproachestoExploreMolecularDiversity

肝细胞癌的遗传学:探索分子多样性的治疗方法

StefanoCaruso,DanielR.O’Brien,SeanP.Cleary,LewisR.Roberts,andJessicaZucman-Rossi

Hepatology.JanuaryVolume73?Supplement14-26

4

MultipleRolesforHepatitisBandCVirusesandtheHostintheDevelopmentofHepatocellularCarcinoma

乙型和丙型肝炎病毒与宿主在肝细胞癌发生中的多重作用

KirkJ.WangensteenandKyong‐MiChang

Hepatology.JanuaryVolume73?Supplement27-37

5

BiologyandClinicalApplicationofRegulatoryRNAsinHepatocellularCarcinoma

调节性RNA在肝细胞癌中的生物学及临床应用

AntonioPea,NigelB.Jamieson，andChiaraBraconi

Hepatology.JanuaryVolume73?Supplement38-48

6

RoleoftheMammalianTargetofRapamycinPathwayinLiverCancer:FromMolecularGeneticstoTargetedTherapies

雷帕霉素途径的哺乳动物靶标在肝脏中的作用:从分子遗传学到靶向治疗

XinjunLu,PanagiotisPaliogiannis,DiegoF.Calvisi,andXinChen

Hepatology.JanuaryVolume73?Supplement49-61

7

MolecularTargetsinCholangiocarcinoma

胆管癌的分子靶点

ColmJ.O’Rourke,PatriciaMunoz-Garrido,andJesperB.Andersen

Hepatology.JanuaryVolume73?Supplement62-74

8

TheTumorMicroenvironmentinCholangiocarcinomaProgression

胆管癌进展中的肿瘤微环境

LucaFabris,KeisakuSato,GianfrancoAlpini,andMarioStrazzabosco

Hepatology.JanuaryVolume73?Supplement75-85

9

LiverCancerImmunity

肝癌免疫

SumeraRizvi,JuanWang,andAnthonyB.El‐Khoueiry

Hepatology.JanuaryVolume73?Supplement86-

10

ImprovingtheEfficacyofLiverCancerImmunotherapy:ThePowerofCombinedPreclinicalandClinicalStudies

改善肝癌免疫治疗的功效:临床前和临床相结合的力量

Gen-ShengFeng,KaisaL.Hanley,YanLiang,andXiaoxueLin

Hepatology.JanuaryVolume73?Supplement-

11

BiomarkersforHepatobiliaryCancers

肝胆癌的生物标记物

Jean-CharlesNaultandAugustoVillanueva

Hepatology.JanuaryVolume73?Supplement-

12

SurgicalTreatmentsofHepatobiliaryCancers

肝胆癌的外科治疗

GaneshGunasekaran,YukiBekki,VennisLourdusamy,andMyronSchwartz

Hepatology.JanuaryVolume73?Supplement-

13

LocalandRegionalTherapiesforHepatocellularCarcinoma

肝细胞癌的局部和区域疗法

RomanKloeckner,PeterRobertGalle,andJordiBruix

Hepatology.JanuaryVolume73?Supplement-

14

EvolutionofSystemicTherapyforHepatocellularCarcinoma

肝细胞癌全身治疗的演变

RichardS.FinnandAndrewX.Zhu

Hepatology.JanuaryVolume73?Supplement-

15

TrialDesignandEndpointsinHepatocellularCarcinoma:AASLDConsensusConference

肝细胞癌的试验设计和终点:AASLD共识会议

JosepM.Llovet,AugustoVillanueva，etal

Hepatology.JanuaryVolume73?Supplement-

Hepatology[Jour]AND73[volume]ANDl[issue]

肝脏病学73卷1期

HepatologyHighlights

肝病学要点

JinendraSatiya,SatinderP.Kaur,DarylT.Y.Lau,etal

Hepatology.Jan;73(1)1-3

Editorials(社论)

1

Doublecortin‐LikeKinaseProtein1inCholangiocarcinoma:IsThistheBiomarkerandTargetWeHaveBeenLookingFor?

胆管癌中的双皮质素激酶蛋白1：这是我们一直在寻找的生物标志物和靶标吗？

VikMeadowsandHeatherFrancis

Hepatology.Jan;73(1)4-6SeeArticleonPages

2

SelectionofPatientsWithCirrhosisForSurgery:AsMuchanArtasScience

肝硬化患者外科手术的选择:科学之门

DouglasA.Simonetto,VijayH.Shah,andPatrickS.Kamath

Hepatology.Jan;73(1)7-9SeeArticleonPages

OriginalArticles(原创文章)

VIRALHEPATITIS(病毒性肝炎)

3

TransmissionofRatHepatitisEVirusInfectiontoHumansinHongKong:AClinicalandEpidemiologicalAnalysis

大鼠戊型肝炎病毒在香港传染给人类：临床和流行病学分析

SiddharthSridhar,CyrilChik‐YanYip,etal

Hepatology.Jan;73(1)10-22

4

HepatitisBVirus–TelomeraseReverseTranscriptasePromoterIntegrationHarnessesHostELF4,ResultinginTelomeraseReverseTranscriptaseGeneTranscriptioninHepatocellularCarcinoma

乙型肝炎病毒-端粒酶逆转录酶启动子整合利用宿主ELF4，导致肝细胞癌端粒酶逆转录酶基因转录

KarenMan-FongSze,DanielWai-HungHo,Yung-TuenChiu,Yu-ManTsui,Lo-KongChan,etal

Hepatology.Jan;73(1)23-40

5

RapidTurnoverofHepatitisBVirusCovalentlyClosedCircularDNAIndicatedbyMonitoringEmergenceandReversionofSignature‐MutationinTreatedChronicHepatitisBPatients

通过监测已治疗的慢性乙型肝炎患者的特征突变的出现和逆转，表明乙型肝炎病毒共价闭合环状DNA的快速周转

QiHuang,BinZhou,DaweiCai,YuhuaZong,etal

Hepatology.Jan;73(1)41-52

6

Toll‐LikeReceptor8AgonistGS‐InducesSustainedEfficacyintheWoodchuckModelofChronicHepatitisB

类似Toll的受体8激动剂GS‐在慢性乙型肝炎的土拨鼠模型中诱导持续疗效

StephaneDaffis,ScottBalsitis,JasonChamberlain,etal

Hepatology.Jan;73(1)53-67

7

ComparativeEffectivenessofEntecavirVersusTenofovirforPreventingHepatocellularCarcinomainPatientswithChronicHepatitisB:ASystematicReviewandMeta‐Analysis

恩替卡韦和替诺福韦预防慢性乙型肝炎患者肝细胞癌的比较疗效:系统评价和Meta分析

ShravanDave,SooyoungPark,M.HassanMurad,AbbeyBarnard,etal

Hepatology.Jan;73(1)68-78

8

AdaptiveNaturalKillerCellFunctionalRecoveryinHepatitisCVirusCuredPatients

丙型肝炎病毒治愈患者的适应性自然杀伤细胞功能恢复

DalilaMele,BarbaraOliviero,StefaniaMantovani,etal

Hepatology.Jan;73(1)79-90

STEATOHEPATITISANDMETABOLICLIVERDISEASE(脂肪性肝炎和代谢性肝病)

9

N6‐MethyladenosineReaderProteinYT‐BHomologyDomain‐Containing2SuppressesLiverSteatosisbyRegulationofmRNAStabilityofLipogenicGenes

N6-甲基腺苷读取器蛋白YT-B同源域包含2通过调节致脂基因mRNA的稳定性抑制肝脂肪变性

BingZhou,CaizhiLiu,LingyanXu,YouwenYuan,etal

Hepatology.Jan;73(1)91-

10

HepaticRegulatorofGProteinSignaling5AmelioratesNonalcoholicFattyLiverDiseasebySuppressingTransformingGrowthFactorBeta–ActivatedKinase1-c-Jun-N-TerminalKinase/p38Signaling

肝调节剂G蛋白信号传导5通过抑制转化生长因子β-活化的激酶1–c‐Jun‐N末端激酶/p38信号传导改善非酒精性脂肪性肝病

JunyongWang,JunpengMa,HongyuNie,etal

Hepatology.Jan;73(1)-

11

TheCommensalMicrobeVeillonellaasaMarkerforResponsetoanFGF19AnaloginNASH

共生微生物Veillonella作为标记用于响应于FGF19模拟在NASH

RohitLoomba,LeiLing,DuyM.Dinh,AlexM.DePaoli,HsiaoD.Lieu,StephenA.Harrison,andArunJ.Sanyal

Hepatology.Jan;73(1)-

HEPATOBILIARYMALIGNANCIES(肝胆恶性肿瘤)

12

DCLK1,aPutativeStemCellMarkerinHumanCholangiocarcinoma

DCLK1，人类胆管癌的推定干细胞标记物

NeviLorenzo,DiMatteoSabina,CarpinoGuido,ZizzariIlaria,SafarikiaSamira,etal

Hepatology.Jan;73(1)-

13

TheIKKβ‐USP30‐ACLYAxisControlsLipogenesisandTumorigenesis

IKKβ-USP30-ACLY轴控制脂肪生成和肿瘤发生

LiGu,YahuiZhu,XiLin,BingjunLu,etal

Hepatology.Jan;73(1)-

14

Plant‐BasedandAnimal‐BasedLow‐CarbohydrateDietsandRiskofHepatocellularCarcinomaAmongUSMenandWomen

以植物和动物为基础的低碳水化合物饮食与美国男性和女性肝细胞癌的风险

YueLiu,WanshuiYang,TrangVoPham,YananMa,TraceyG.Simon,XiangGao,etal

Hepatology.Jan;73(1)-

AUTOIMMUNE,CHOLESTATICANDBILIARYDISEASE(自身免疫，胆汁淤积和胆道疾病)

15

SyntheticConjugatesofUrsodeoxycholicAcidInhibitCystogenesisinExperimentalModelsofPolycysticLiverDisease

熊去氧胆酸的合成缀合物抑制多囊性肝病实验模型中的膀胱发生

FranciscoJ.Caballero‐Camino,IvanRivilla,etal

Hepatology.Jan;73(1)-

LIVERFAILURE,CIRRHOSISANDPORTALHYPERTENSION(肝衰竭，肝硬化和门脉高压)

16

RiskPredictionModelsforPost‐OperativeMortalityinPatientsWithCirrhosis

肝硬化患者手术后死亡率的风险预测模型

NadimMahmud,ZacharyFricker,etal

Hepatology.Jan;73(1)-

17

MortalityandHepaticDe

转载请注明：http://www.jzhuangx.com/gsjys/7471.html